PMID: 9533724Apr 9, 1998Paper

Streptococcus mitis with unusually high level resistance to beta-lactam antibiotics

Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease
A KönigRegine Hakenbeck

Abstract

Penicillin-resistant oral streptococci constitute the genetic reservoir for beta-lactam resistance in S. pneumoniae. Here we report the isolation of clinical strains of S. mitis with unusually high MIC values for beta-lactam antibiotics; resistance to benzylpenicillin was 64 microg/ml and to cefotaxime 128 microg/ml. Among the beta-lactam compounds tested, only the carbapenems imipenem and meropenem showed MICs below 32 microg/ml. Both S. mitis strains were resistant to tetracycline and were highly resistant to aminoglycosides. Pulse field mapping of chromosomal DNA revealed identical patterns in both strains, indicating clonal identity of the two isolates. Using chromosomal S. mitis DNA, the laboratory strain S. pneumoniae R6 could be transformed in four successive steps to cefotaxime and benzylpenicillin resistance of 64 microg/ml. The results exemplify the importance of commensal streptococci for the development of cefotaxime resistance in S. pneumoniae.

References

Jan 1, 1991·Applied Microbiology and Biotechnology·B BräuA Pühler
Feb 16, 1991·Lancet·P H McWhinneyH G Prentice
Sep 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J T van der MeerM F Michel
Aug 1, 1991·The Journal of Infectious Diseases·R HakenbeckC Martin
Aug 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·C G DowsonB G Spratt
Apr 1, 1989·Antimicrobial Agents and Chemotherapy·M VendittiP Martino
Aug 11, 1987·Nucleic Acids Research·M McClellandM Nelson
Mar 1, 1987·Journal of General Microbiology·R HakenbeckN F Adkinson
Jan 1, 1968·Journal of General Microbiology·G Colman
Jan 1, 1983·Journal of the American College of Cardiology·R O BrandenburgJ E Geraci
Sep 1, 1981·The Journal of Pediatrics·R A BroughtonC J Baker
Aug 1, 1994·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H F GuiotJ M Vossen
Jan 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·P Y BochudP Francioli
Sep 1, 1995·Antimicrobial Agents and Chemotherapy·J L MainardiF W Goldstein
Dec 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R R ReinertR Lütticken
Apr 1, 1995·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·E Potgieter, L J Chalkley
Aug 1, 1957·The Journal of Experimental Medicine·R M BRACCOC M MACLEOD
Apr 22, 1960·Biochimica Et Biophysica Acta·S LACKS, R D HOTCHKISS

❮ Previous
Next ❯

Citations

Mar 6, 1999·Current Opinion in Microbiology·A MorrisD E Low
Apr 28, 2001·Journal of Clinical Microbiology·R R ReinertUNKNOWN Multicenter Study on Antibiotic Resistance in Staphylococci and other Gram-positive Cocci (MARS) Study Group
Dec 12, 2012·Journal of Molecular Microbiology and Biotechnology·Angelika RothRegine Hakenbeck
Mar 3, 2010·PloS One·Dalia DenapaiteRegine Hakenbeck
Dec 24, 2003·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Ayako Nakayama, Ayuko Takao
Mar 3, 2004·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hiroyuki UsuiKatsunori Ishibashi
Feb 4, 2016·Journal of Biological Inorganic Chemistry : JBIC : a Publication of the Society of Biological Inorganic Chemistry·Shams Tabrez KhanAbdulaziz A Al-Khedhairy
Apr 27, 2007·International Journal of Medical Microbiology : IJMM·Fang ChiRegine Hakenbeck
Aug 11, 2001·Critical Reviews in Oral Biology and Medicine : an Official Publication of the American Association of Oral Biologists·D G Cvitkovitch
Dec 2, 2017·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Mark van der LindenRegine Hakenbeck
Apr 8, 2015·Antimicrobial Agents and Chemotherapy·Anders JensenMogens Kilian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Cell Wall Structure (ASM)

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Bacterial Cell Wall Structure

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.